Despite the sales collapse of asthma drug Singulair, the drug maker still has other ways to grow.

The drug maker announced its earnings results on Friday morning and the results were arguably mixed. Excluding one-time items, operating earnings did rise by a penny to 95 cents a share, beating consensus estimates of 92 cents a share. Lower merger costs and a favorable tax rate helped buoy...